Societatea de Obstetrica Ginecologie din Romania


Asociatia Romana de Urologie


Societatea de Uroginecologie din Romania




Vezica hiperactiva (OAB - overactive bladder) caracterizata prin imperiozitatea senzatiei de a urina cu pierderea involuntara de cantitati variate de urina este o conditie patologica care afecteaza viata a peste 50 de milioane de persoane din intreaga lume, incidenta crescand odata cu varsta.

Urgenta mictionala care determina simptomatologia specifica vezicii hiperactive este rezultatul unei reactii exagerate contractile a muschiului detrusor vezical la stimulul fiziologic reprezentat de umplerea vezicala cu urina. Mai frecvent la femei fata de barbati ea poate fi insotita de incontinenta urinara de efort cu pierderea involuntara de cantitati variate de urina la grade diferite de efort fizic.

Ameliorarea acestei simptomatologii se poate realiza prin administrarea de agenti medicamentosi noi, cu avantaje nete prin incidenta mult diminuata a reactiilor adverse, prin modalitatea simpla de administrare (doza unica zilnica) si avand efect si asupra nocturiei (urinare frecventa in cursul noptii).

Referinte
1. „(...): as effective in mixed urinary incontinence as in urge urinary incontinence” – Con Kelleher, Linda Cardozo, Kathelen Kobashi, Vincent Lucente – International Urogynecology Journal, 4 sept. 2005. 2. „Efficacy of (...) in patients with severe symptoms of overactive bladder: a pooled analysis” – R.J.Millard and M. Halaska – Current Medical Research and Opinion, vol 22, No. 1, 41-48, 2006. 3. „A Comparision of the Efficacy and Tolerability of (...) and Extended release (...) at treating Overactive Bladder syndrome: Results of the STAR Trial” – C.R. Chapple, R. Martinez-Garcia, L. Selvaggi, P. Toozs-Hobson, W. Warnack, T. Drogendij, D.M. Wright, J. Bolodeoku – European Urology, for the Star study group, 16 iunie 2005. 4. „Improved quality of life in patients with overactive bladder symptoms treated with (...)” – Con J. Kelleher, Linda Cardozo, C. R. Chappelet, F. Habbt, A. Ridder – BJU International 2005 95,81-85. 5. „Randomized, double blind placebo controlled trial of the once daily antimuscarinic agent (...) in patients with overactive bladder” – L. Cardozo, M. Lisec, R. Millard, O. Van Vierssen Trip, I. Kuymin, TE Drogendijk, M. Huang, M. Ridder- The Journal of Urology, vol 172, nr 5 ,noiembrie 2004. 6. „Long term open label (...) treatment associated with persistence with therapy in patients with Overactive Bladder Syndrome” – F. Haab, L. Cardozo, C. Chapple, AM. Ridder – European Urology 47, 2005 7. „Lower urinary tract – Randomized, double-blind placebo and (...)-controlled trial of the once-daily antimuscarinic agent (...) in patients with symptomatic overactive bladder” – CR. Chapple, T. Rechberger, S. Al-Shukrit, P. meffan, k. Everaert, m. Huangs, A. Ridder – BJU International, 93, 303-310, oct 2003. 8. „Long term open-label (...)treatment Associated with Persistence with therapy in patients with overactive bladder syndrome” – F. Haab, L. Cardozo, C. Chapple, AM. Ridder – Europeann Urology 47, 2005.

Seful Clinicii de Obstetrica-Ginecologie
Spitalul de Urgenta "Sf. Pantelimon"
Academician Profesor Doctor Virgiliu Ancar



« inapoi